Atricure reports third quarter 2024 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced third quarter 2024 financial results. “our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said michael carrel, president and chief executive officer at atricure. “during the quarter, we launched sev.
ATRC Ratings Summary
ATRC Quant Ranking